Rac1 as a Potential Pharmacodynamic Biomarker for Thiopurine Therapy in Inflammatory Bowel Disease
Margien L. Seinen, Adriaan A. van Bodegraven(Maastricht University Medical Centre)
Cited by 29
Related Papers
Safety and Effectiveness of Long-term Allopurinol–Thiopurine Maintenance Treatment in Inflammatory Bowel Disease
|Inflammatory Bowel Diseases|2012|102
Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry
|Alimentary Pharmacology & Therapeutics|2020|87
Clinical Outcomes of Covid-19 in Patients With Inflammatory Bowel Disease: A Nationwide Cohort Study
|Journal of Crohn s and Colitis|2020|71